Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
November 2018
-
Story From Our Labs
Women in Science: Alexandra Bach-Weidmuller
Alexandra Bach-Weidmuller, Head of Program and Project Management at NIBR, describes her path to leadership as lateral instead of upward.
-
Media Release
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
26 potential blockbusters in confirmatory development[1]. 13 projects in clinical development across Cell, Gene & Radioligand therapies. 60 major submissions[2] planned from 2019 to 2021… -
Media Release
Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs
Decision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is… -
Media Release
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2-… -
Story Patient Perspectives
The realities of living with premenopausal metastatic breast cancer
Receiving a breast cancer diagnosis is difficult, but these young women faced an especially challenging diagnosis: stage IV metastatic breast cancer.
-
Story Patient Perspectives
The importance of caregivers
Melanoma survivor T.J. Sharpe discusses his personal experience with cancer and the important role caregivers play in a patient’s road to recovery.
October 2018
-
Media Release
Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz)
Biosimilar HyrimozTM (adalimumab-adaz) approved for all indications of reference medicine not protected by orphan exclusivity **Biosimilars are critical to sustaining US healthcare system, providing… -
Media Release
Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
Agreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH) Novartis has… -
Media Release
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in… -
Story People and Culture
Flexibility at Novartis: Robert Gschwentner and Stefan Lackner
Gschwentner and Lackner discuss the advantages of their job share.
-
Story People and Culture
Flexibility at Novartis: Ana Graf
Graf explains how flexible working has contributed to her success.
-
Media Release
Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis
New Cosentyx® (secukinumab) label to include dosing flexibility up to 300 mg, based on clinical response, and 24-week structural data with subcutaneous (sc) regimens[1] Cosentyx inhibits…